[josephmorale]

Roots Analysis has announced the addition of “Bacteriophage Therapeutics Market, 2022-2035” report to its list of offerings.

 

Key Market Insights

§  Over 100 bacteriophage therapeutics have either been marketed / are being developed by various well-established and small firms; majority of these therapeutics are being evaluated for the treatment of infectious diseases

§  Around 50% of the pipeline candidates are currently under clinical phase of development; of these, close to 50% are designed for oral and topical administration

§  Multiple clinical studies, evaluating various types of bacteriophage therapeutics among more than 3,000 patients across different centers / hospitals, have been registered worldwide

§  Over the years, the intellectual capital related to bacteriophage therapeutics has grown at a significant pace, with several patents being filed by both industry and non-industry players

§  A notable increase in published scientific literature related to bacterio-phage therapeutics has been observed over the years, demonstrating the growing interest in this domain

§  Various organizations have extended financial support to aid the ongoing research for bacteriophage therapies; currently, the focus, in terms of funds disbursed, is on clinical investigation of bacteriophage therapeutics

§  Several investors, having realized the benefits and future opportunity, have invested over USD 1 billion since 2017

§  The rising interest of stakeholders is also reflected by the number of partnerships signed in the recent past, involving players located in different geographical regions

§  Our proprietary start-up health indexing analysis confirms the presence of several new entrants that claim to possess the required capabilities for developing bacteriophage therapeutics

§  The bacteriophage market is anticipated to grow at a CAGR of ~10% till 2035; the forecasted opportunity is likely to be distributed across different therapeutic areas, routes of administration, and geographical regions

 

Table of Content

1.                     PREFACE

1.1.                  Scope of the Report

1.2.                  Market Segmentations

1.3.                  Research Methodology

1.4.                  Key Questions Answered

1.5.                  Chapter Outlines

 

2.                     EXECUTIVE SUMMARY

 

3.                     INTRODUCTION

3.1.                  Chapter Overview

3.2.                  Historical Evolution of Bacteriophages

3.3.                  Biology of Bacteriophages

3.4.                  Introduction to Bacteriophage Therapy

3.5.                  Applications of Bacteriophage Therapy

3.6.                  Advantages of Bacteriophage Therapy

3.7.                  Limitations of Bacteriophage Therapy

3.8.                  Conclusion

 

4.                     BACTERIOPHAGE THERAPEUTICS: MARKET LANDSCAPE

4.1.                  Chapter Overview

4.2.                  Bacteriophage Therapeutics: Drug Pipeline

4.2.1.               Analysis by Phase of Development

4.2.2.               Analysis by Therapeutic Area

4.2.3.               Analysis by Phase of Development and Therapeutic Area

4.2.4.               Analysis by Targeted Bacterial Strain

4.2.5.               Analysis by Target Disease Indication

4.2.6.               Analysis by Type of Therapy

4.2.7.               Analysis by Route of Administration

 

4.3.                  Information on Bacteriophage Related Technologies

 

5.                     BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE

5.1.                  Chapter Overview

5.2.                  Bacteriophage Therapeutics: List of Developers

5.2.1.               Analysis by Year of Establishment

5.2.2.               Analysis by Company Size

5.2.3.               Analysis by Location of Headquarters

5.2.4.               Analysis by Company Size and Location of Headquarters

5.2.5.               Leading Developers: Analysis by Number of Bacteriophage Therapeutics

 

6.                     COMPANY AND DRUG PROFILES

6.1.                  Chapter Overview

6.2.                  Eliava BioPreparations

6.3.                  Micreos

6.4.                  NPO Microgen

6.5.                  ContraFect

6.6.                  Adaptive Phage Therapeutics

6.7.                  Phagelux

6.8.                  Pherecydes Pharma

 

7.                     CLINICAL TRIAL ANALYSIS

7.1.                  Chapter Overview

7.2.                  Scope and Methodology

 

7.3.                  Bacteriophage Therapeutics Market: Clinical Trial Analysis

 

8.                     PATENT ANALYSIS

8.1.                  Chapter Overview

8.2.                  Scope and Methodology

 

8.3.                  Bacteriophage Therapeutics: Patent Analysis

 

8.4.                  Bacteriophage Therapeutics: Patent Benchmarking

8.5.                  Bacteriophage Therapeutics: Patent Valuation

8.6.                  List of Leading Patents

 

9.                     PUBLICATION BENCHMARKING ANALYSIS

9.1.                  Chapter Overview

9.2.                  Scope and Methodology

9.3.                  Publication Benchmarking

 

10.                   ACADEMIC GRANTS ANALYSIS

10.1.                Chapter Overview

10.2.                Scope and Methodology

 

10.3.                Bacteriophage Therapeutics: Academic Grant Analysis

 

11.                   FUNDING AND INVESTMENT ANALYSIS

11.1.                Chapter Overview

11.2.                Types of Funding

11.3.                Bacteriophage Therapeutics Market: List of Funding and Investments

11.4.                Concluding Remarks

 

12.                   PARTNERSHIPS AND COLLABORATIONS

12.1.                Chapter Overview

12.2.                Partnership Models

12.3.                Bacteriophage Therapeutics: List of Partnerships and Collaborations

 

13.                   START-UP HEALTH INDEXING

13.1.                Chapter Overview

13.2.                Bacteriophage Therapeutics Developers: Start-ups

13.3.                Benchmarking of Start-ups

 

14.                   MARKET FORECAST AND OPPORTUNITY ANALYSIS

14.1.                Chapter Overview

14.2.                Scope and Assumptions

14.3.                Forecast Methodology

14.4.                Global Bacteriophage Therapeutics Market, 2022-2035

 

15.                   CONCLUSION

 

16.                   EXECUTIVE INSIGHTS

16.1.                Chapter Overview

16.2.                Rime Bioinformatics

16.2.1.             Company Snapshot

16.2.2.             Interview Transcript: Antoine Culot, Chief Executive Officer

 

16.3.                BiomX

16.4.                Hospices Civils De Lyon

16.5.                Independent Consultant

 

17.                   APPENDIX I: TABULATED DATA

 

18.                   APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

 

For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html

 

You may also be interested in the following titles:

Nanoparticle Formulation Market

mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends

Cell Therapy Manufacturing Market

Roots Analysis Consulting – the preferred research partner for global firms

 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

 

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com

 

 

[Автор]

Пости